Invest24

Appearance

Novo Nordisk ​

Financial results ​

News ​

Novo Nordisk intends to reduce the global workforce by approximately 9,000 of the 78,400 positions in the company, with around 5,000 reductions expected in Denmark.

Over the past years, Novo Nordisk’s rapid scaling has increased organisational complexity and costs.

The workforce reduction is expected to deliver total annualised savings of around DKK 8 billion by the end of 2026.

The company-wide transformation comes with an expected DKK 8 billion in net one-off restructuring costs, including impairment charges. Restructuring costs of around DKK 9 billion will be incurred in the third quarter of 2025, countered by savings of around DKK 1 billion in the fourth quarter. Consequently, Novo Nordisk expects an estimated one-off negative impact of around 6 percentage points on full-year operating profit growth at CER in 2025 compared to the operating profit outlook issued 6 August.

Outlook 2025

  • Expectations 6 August
    • Operating profit growth (EBIT) at CER: 10-16%
    • Depreciation, amortisation and impairment losses: Around DKK 17 billion
  • Expectations 10 September:
    • Operating profit growth (EBIT) at CER: 4-10%
    • Depreciation, amortisation and impairment losses: Around DKK 21 billion

CER = Constant Exchange Rates

Aug. 18, 2025-- GoodRx (Nasdaq: GDRX), the leading platform for medication savings in the U.S., today announced that via a collaboration with Novo Nordisk, all strengths of Ozempic® (semaglutide) and Wegovy® (semaglutide) pens are available to eligible self-paying patients for $499-per-month through GoodRx, effective today.

2025Q2 ​

Lars Fruergaard Jørgensen, president and CEO: "While delivering 18% sales growth in the first half of 2025, we have lowered our full-year outlook due to lower growth expectations for our GLP-1 treatments in the second half of 2025. As a result, we are taking measures to sharpen our commercial execution further, and ensure efficiencies in our cost base while continuing to invest in future growth. With more than one billion people living with obesity globally, including more than 100 million living in the US, and only a few million on treatment, I am confident that under Mike Doustdar's leadership, Novo Nordisk will maximise the significant growth opportunities, supported by a strong product portfolio and future pipeline".

2025Q1 ​